Overview

A Phase 3 Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Active Behçet's Disease

Status:
Completed

Trial end date:
2020-07-17

Target enrollment:

Participant gender:

Summary

The main objective of this study is to evaluate the efficacy and safety of apremilast in the treatment of oral ulcers in adults with active Behçet's disease (BD).

Phase:

Phase 3

Details

Lead Sponsor:

Amgen
Celgene Corporation

Treatments:

Apremilast
Thalidomide